BioXcel Therapeutics, Inc. (BTAI): IPOs News

BTAI – Prices upsized 5.45 mln share IPO (from 5 mln shares) at $11.00, the low-end of the expected $11.00-13.00 range.

Key Facts Surrounding This News Item

  • BTAI had returned 0.00% year-to-date leading up to today’s news, versus a +2.22% return from the benchmark S&P 500 during the same period.

More Info About BioXcel Therapeutics, Inc. (BTAI)

BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers. It is also developing BXCL502, a novel approach to the treatment of symptoms resulting from neurological disorders; and BXCL702, an immuno-oncology agent for hematological malignancies. The company was founded in 2017 and is based in Branford, Connecticut. BioXcel Therapeutics, Inc. is a subsidiary of BioXcel Corporation. View our full BTAI ticker page with ratings, news, and more.

BTAI at a Glance

BTAI Current POWR Rating™
Overall POWR Rating™
BTAI Current Price $4.18 8.13%
More BTAI Ratings, Data, and News

BTAI Price Reaction

The day of this event (Mar. 8, 2018)
BTAI Closing Price$11.03 N/A%
BTAI Volume1,910,500
N/A% from avg
Leading up to this event
BTAI 1-mo returnN/A%
After this event
BTAI 1-day returnN/A%
BTAI 3-day returnN/A%
BTAI 5-day returnN/A%

BTAI Price Chart

The Top Stocks For 2019

More BioXcel Therapeutics, Inc. (BTAI) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All BTAI News
Page generated in 0.8059 seconds.